<DOC>
	<DOCNO>NCT00002854</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus peripheral stem cell transplantation treat patient advanced cancer .</brief_summary>
	<brief_title>High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate feasibility administer 2 course high dose chemotherapy consist etoposide , cisplatin , cyclophosphamide follow ifosfamide , carboplatin , paclitaxel ( IC-T ) , administer filgrastim ( G-CSF ) autologous stem cell support , patient advance carcinoma . - Describe toxicity high dose chemotherapy regimen . - Define maximum tolerate dose paclitaxel deliverable high dose regimen . - Describe pharmacokinetics escalate dos paclitaxel give 24-hour continuous infusion . - Determine disposition carboplatin administer IC-T regimen . OUTLINE : At least 4 week prior chemotherapy , patient undergo stem cell collection follow filgrastim ( G-CSF ) mobilization . Sufficient stem cell support 2 course chemotherapy require . Autologous bone marrow collect adjuvant stem cell harvest inadequate . Patients receive high dose cisplatin , etoposide , cyclophosphamide 10 day , follow next day infusion one fourth allotted stem cell , remain allotment infuse 2 day later . G-CSF give granulocyte support . Beginning sooner 14 week start first course chemotherapy , stable respond patient receive high dose paclitaxel , carboplatin , ifosfamide 5 day , follow 2 day later one-fourth allotted stem cell , remain allotment infuse following day . G-CSF give granulocyte support . Groups 3-6 patient treat escalate dos paclitaxel maximum tolerate dose regimen determine . Patients follow monthly 1 year , every 3 month 1 year , need physician 's discretion least 5 year . PROJECTED ACCRUAL : Three six patient enter dose paclitaxel study .</detailed_description>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced carcinoma follow type : Breast carcinoma ineligible patient refuse participation high priority protocol follow category : Stage II disease least 10 involved lymph node evidence disease ( NED ) follow surgery Stage III disease render surgically NED without radiotherapy Stage IV disease follow partial response ( PR ) complete response ( CR ) surgery , chemotherapy , radiotherapy Prior high dose chemotherapy allow discretion investigator No chemoresistant disease render surgically NED Locoregionally recurrent disease within 2 year breast conservation without chemotherapy Stage III/IV ovarian cancer PR/CR follow debulking surgery and/or chemotherapy Ineligible refuse participation high priority protocol Primary soft tissue sarcoma highgrade disease great 10 cm metastatic Rendered surgically NED achieve PR/CR chemotherapeutic immunotherapeutic regimen Ineligible refuse participation high priority protocol Malignant melanoma follow category : Ulcerative primary tumor number completely resect metastatic lymph node Stage II disease 4 involve node render NED Stage III disease render surgically NED achieve PR/CR chemotherapeutic immunotherapeutic regimen Osteosarcoma ineligible refuse participation high priority protocol Resected primary less 50 % tumor necrosis pathologic review Metastatic disease render surgically NED PR/CR chemotherapeutic , radiotherapeutic , immunotherapeutic regimen The following disease render surgically NED achieve PR/CR chemotherapeutic , radiotherapeutic , immunotherapeutic regimen also eligible : Small cell bone carcinoma Metastatic Ewing 's sarcoma Metastatic gastrointestinal malignancy Recurrent Wilms ' tumor No CNS metastases No current histologically confirm bone marrow metastases Prior bone metastases resolution time entry permit PATIENT CHARACTERISTICS : Age : Physiologic 18 55 Performance status : Karnofsky 80 % 100 % Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 120,000/mm3 Hemoglobin great 10 g/dL Hepatic : Bilirubin le 1.5 mg/dL AST/ALT le 3 time normal Renal : Creatinine le 1.4 mg/dL Creatinine clearance least 70 mL/min No history hemorrhagic cystitis Cardiovascular : Ejection fraction least 55 % MUGA No significant cardiac disease Pulmonary : FEV1 great 2 L pO2 ( room air ) great 70 mm Hg pCO2 ( room air ) less 42 mm Hg DLCO great 60 % predict Other : No potentially disable psychosocial history No organic functional CNS dysfunction medical problem would present party undue risk HIV negative Hepatitis B surface antigen negative No hearing loss great 40 decibel No contraindication follow procedure : Collection apheresis 16 x 10 8th mononuclear cell mobilize GCSF Collection autologous bone marrow , need No second malignancy except : Nonmelanomatous skin cancer Carcinoma situ cervix Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior immunotherapy Chemotherapy : See Disease Characteristics No 3 prior chemotherapy regimen ( exclude adjuvant therapy ) No 200 mg per square meter prior cisplatin No 800 mg per square meter prior carboplatin No prior exposure great 1,000 mg per square meter `` 24hour paclitaxel equivalent '' ( use 1:1.3 ratio paclitaxel dose give 24hour infusion 3hour infusion ) At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 20 % bone marrow At least 4 week since prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>localize osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>stage II melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>